How should remitting seronegative symmetrical synovitis with pitting edema (RS3PE) in a patient over 60 presenting with sudden bilateral hand and knee edema be evaluated and managed?

RS3PE: Evaluation and Management

In a patient over 60 with sudden bilateral hand and knee edema, immediately refer to rheumatology within 6 weeks, obtain RF, anti-CCP, ANA, CBC, ESR/CRP, and initiate low-to-moderate dose glucocorticoids (prednisone 10-20 mg/day) after ruling out malignancy with age-appropriate cancer screening. 1, 2

Initial Diagnostic Approach

Clinical Recognition

RS3PE presents with:

• Sudden-onset symmetrical pitting edema of hands (dorsal surfaces) and sometimes feet
• Symmetrical (teno-)synovitis of large and small joints
• Occurs predominantly in patients >60 years old
• Positive "squeeze test" of metacarpophalangeal/metatarsophalangeal joints 1

Essential Laboratory Workup

Obtain the following tests to confirm seronegative status and exclude mimics 1, 2:

• Rheumatoid factor (RF) - must be negative
• Anti-CCP antibodies - must be negative
• Antinuclear antibodies (ANA) - typically negative
• ESR and CRP - usually markedly elevated 3
• Complete blood count
• Urinalysis
• Transaminases

Critical Differential Diagnoses to Exclude

Malignancy screening is mandatory - RS3PE can be paraneoplastic in a significant proportion of cases 4, 5, 6. The guideline explicitly lists RS3PE among mimicking diseases that must be considered when evaluating difficult-to-treat arthritis 4.

Other conditions to rule out 4:

• Crystal arthropathies (gout, pseudogout) - examine joint fluid for crystals
• Polymyalgia rheumatica
• Rheumatoid arthritis (though RF/anti-CCP negative)
• Psoriatic arthritis
• Reactive arthritis (parvo B19, rubella, HBV/HCV)
• Checkpoint inhibitor-induced arthritis (if on cancer immunotherapy) 5

Imaging Strategy

First-Line Imaging

Clinical examination remains primary, but imaging can confirm synovitis when in doubt 1, 2:

• Ultrasound with power Doppler - detects synovial hypertrophy, tenosynovitis, and enhanced vascularity 2, 7
• Plain radiographs of hands and feet - establish baseline and exclude erosive disease
• MRI if ultrasound unavailable or inconclusive - more sensitive for detecting synovitis and bone marrow edema 2

The 2017 EULAR guidelines emphasize that ultrasound may confirm synovitis when clinical examination is equivocal, which is particularly relevant in RS3PE where dramatic edema can obscure true synovial inflammation 2.

Treatment Algorithm

Initial Management

Glucocorticoids are highly effective and first-line 6, 3:

1. Start prednisone 10-20 mg/day (or equivalent)

   • RS3PE typically shows excellent response within days to weeks 6, 3
   • Lower doses than typically used for polymyalgia rheumatica or RA

2. Taper gradually once symptoms improve:

   • Reduce by 2.5-5 mg every 2-4 weeks
   • Target: lowest effective dose or discontinuation
   • Many patients achieve drug-free remission 6

Refractory Cases

If inadequate response to glucocorticoids or unable to taper 1, 2:

• Consider methotrexate as steroid-sparing DMARD (anchor drug per EULAR guidelines)
• Alternative DMARDs: hydroxychloroquine, sulfasalazine
• Goal: achieve remission while minimizing glucocorticoid exposure

Monitoring Strategy

Follow disease activity at 1-3 month intervals until remission achieved 1, 2:

• Tender and swollen joint counts
• Patient and physician global assessments
• ESR and CRP
• Functional assessment (e.g., HAQ)

Critical Pitfalls to Avoid

1. Missing underlying malignancy - Perform age-appropriate cancer screening (colonoscopy, mammography, PSA, chest imaging) as RS3PE can be paraneoplastic 4, 6

2. Misdiagnosing as infection - Post-arthroplasty RS3PE can mimic periprosthetic joint infection with fever, synovitis, and elevated inflammatory markers. Joint fluid cultures will be negative 8

3. Overlooking checkpoint inhibitor association - In cancer patients on immunotherapy, RS3PE may represent an immune-related adverse event requiring rheumatology consultation 5

4. Delaying rheumatology referral - Patients with polyarticular arthritis should be seen by rheumatology within 6 weeks of symptom onset 1, 2

5. Using excessive glucocorticoid doses - RS3PE responds to moderate doses (10-20 mg/day); higher doses increase toxicity risk without added benefit

Special Considerations

Comorbidities

Recent data suggests high prevalence of metabolic syndrome in RS3PE patients 9:

• 48% have diabetes mellitus (predominantly type 2)
• 60% have hyperlipidemia
• Evaluate and manage cardiovascular risk factors

NSAIDs

May be used for symptomatic relief after assessing gastrointestinal, renal, and cardiovascular status, but are typically insufficient as monotherapy 1, 2

Prognosis

RS3PE generally has a favorable prognosis with appropriate treatment 6, 3. Most patients achieve remission, though some require maintenance DMARD therapy to prevent relapse.